Scholar Rock shares rise amid sector rotation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 19 2026
0mins
Should l Buy SRRK?
Scholar Rock Holding Corp's stock price increased by 14.43% as it crossed above the 5-day SMA, indicating a significant upward movement despite the broader market decline.
The rise in Scholar Rock's shares appears to be driven by sector rotation, as investors shift their focus towards biotechnology stocks amid a challenging market environment. This shift is likely influenced by recent positive developments in the biotech sector, which have attracted investor interest.
This upward movement could signal a growing confidence in Scholar Rock's potential, especially as the company continues to advance its pipeline of therapies targeting muscle disorders.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SRRK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SRRK
Wall Street analysts forecast SRRK stock price to rise
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 43.080
Low
42.00
Averages
50.00
High
60.00
Current: 43.080
Low
42.00
Averages
50.00
High
60.00
About SRRK
Scholar Rock Holding Corporation is a late-stage biopharmaceutical company. It is focused on advancing treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. Its product candidate, apitegromab, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as a potential first muscle-targeted therapy for the treatment of SMA. Its products include SRK-439, SRK-181, SRK-373 and SRK-256. SRK-181 is a selective inhibitor of the activation of latent TGFb1, is being developed for the treatment of cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Scholar Rock Resubmits Apitegromab BLA to FDA
- BLA Resubmission: Scholar Rock has resubmitted the Biologics License Application (BLA) for Apitegromab to the FDA, anticipating acceptance within 30 days and a review period of up to six months, which could provide new treatment options for SMA patients.
- Facility Expansion: The resubmission includes a second U.S.-based fill-finish facility aimed at strengthening the supply chain for Apitegromab to meet growing market demand, thereby enhancing the company's competitive position globally.
- Positive FDA Interactions: Scholar Rock's frequent and constructive interactions with the FDA, particularly during the Q1 2026 meeting, have led to alignment on the resubmission process, indicating the FDA's commitment to the drug's approval.
- European Market Progress: The review of the Marketing Authorisation Application (MAA) for Apitegromab in Europe is progressing well, with a decision expected in mid-2026, further supporting the company's global business expansion.
See More
Scholar Rock Resubmits Biologics License Application for SMA Treatment
- Price Target Increase: Raymond James raised Scholar Rock's price target from $53 to $60 while maintaining a ‘Strong Buy’ rating, indicating analysts' confidence in the company's future performance, with expectations of strong market uptake for Apitegromab if approved.
- Regulatory Risk Mitigation: H.C. Wainwright views the resubmission as a ‘material de-risking event’, significantly improving approval chances due to FDA support for manufacturing and increased redundancy, which is expected to accelerate the commercialization process.
- FDA Decision Timeline: The FDA is expected to accept the application within 30 days, followed by a review period of up to six months, with a potential decision by September 2026, providing the company with a clear timeline to prepare for market launch.
- Positive Retail Investor Sentiment: Retail sentiment on Stocktwits shifted from ‘neutral’ to ‘bullish’, indicating strong market interest in Scholar Rock, with the stock gaining approximately 10% year-to-date, reflecting investor confidence in its future potential.
See More
US Stocks Surge as Market Sentiment Improves
- Market Sentiment Improves: The S&P 500 index rose by 1.02%, the Dow Jones Industrial Average increased by 0.67%, and the Nasdaq 100 surged by 1.10% as President Trump signaled a willingness to end military actions against Iran, reflecting investor optimism over easing geopolitical risks.
- Falling Bond Yields: The 10-year Treasury note yield dropped to a one-week low of 4.30%, indicating market expectations that an end to the Iran conflict could lower energy prices and alleviate inflation concerns, further supporting stock market gains.
- Consumer Confidence Rises: The US March consumer confidence index unexpectedly increased by 0.8 to 91.8, surpassing expectations of a decline to 87.9, suggesting enhanced consumer confidence in economic prospects, which could drive spending and economic growth.
- Strong Chinese Economy: China's March manufacturing PMI rose to 50.4, exceeding expectations of 50.1, indicating signs of economic recovery that support global growth prospects and positively influence market performance.
See More
US Stocks Surge as Market Sentiment Improves
- Market Rebound: The S&P 500 Index rose by 1.33%, the Dow Jones Industrial Average increased by 1.10%, and the Nasdaq 100 Index climbed by 1.45%, reflecting investor optimism following President Trump's willingness to end military actions against Iran, potentially easing geopolitical tensions.
- Supportive Economic Data: China's March manufacturing PMI rose by 1.4 to 50.4, surpassing expectations of 50.1, indicating signs of economic recovery that could enhance global growth prospects and drive stock markets higher.
- Falling Bond Yields: The 10-year T-note yield dropped to 4.30%, a one-week low, as WTI crude oil prices fell, alleviating inflation concerns and lowering borrowing costs, thereby supporting further gains in the stock market.
- Tech Stocks Lead Gains: The
See More
Scholar Rock Resubmits Drug Application for Apitegromab, Shares Rise
- Application Resubmission: Scholar Rock announced the resubmission of its U.S. marketing application for apitegromab, aimed at spinal muscular atrophy, resulting in a ~12% premarket share increase, reflecting market optimism regarding potential approval.
- Positive FDA Feedback: Following multiple interactions with the FDA, Scholar Rock confirmed it received guidance on the BLA submission, with no additional corrective actions requested, allowing the company to proceed with the application ahead of Catalent Indiana's reinspection.
- Review Timeline Expectations: The company anticipates that the FDA will accept the BLA within 30 days of resubmission and grant a review period of up to six months, with a potential action date in late September, laying a foundation for future commercialization.
- Ongoing EU Review: The review of Scholar Rock's Marketing Authorization Application for apitegromab in the EU is also underway, with a decision expected in mid-2026, which will further influence the company's international market strategy and development.
See More
Scholar Rock Q4 2025 Earnings Call Insights
- Financial Performance: Scholar Rock reported operating expenses of $91.9 million for Q4 2025, including $19.4 million in noncash stock-based compensation, indicating the company's efforts in cost control while laying the groundwork for future product launches.
- Financial Flexibility: The company ended 2025 with $368 million in cash and cash equivalents and secured a new debt facility of up to $550 million with Blue Owl Capital, enhancing financial flexibility to support the upcoming BLA resubmission and market launch.
- Regulatory Progress: Management reiterated guidance for BLA resubmission of apitegromab in 2026, anticipating FDA approval following a successful reinspection, indicating proactive readiness in regulatory compliance that could expedite product launch timelines.
- Supply Chain Redundancy: Progress has been made on engineering runs at a second fill-finish facility, with plans to file a supplemental BLA later this year, demonstrating a forward-looking approach in supply chain management to mitigate potential production risks and ensure market supply.
See More
Scholar Rock Resubmits Apitegromab BLA to FDA
- BLA Resubmission: Scholar Rock has resubmitted the Biologics License Application (BLA) for Apitegromab to the FDA, anticipating acceptance within 30 days and a review period of up to six months, which could provide new treatment options for SMA patients.
- Facility Expansion: The resubmission includes a second U.S.-based fill-finish facility aimed at strengthening the supply chain for Apitegromab to meet growing market demand, thereby enhancing the company's competitive position globally.
- Positive FDA Interactions: Scholar Rock's frequent and constructive interactions with the FDA, particularly during the Q1 2026 meeting, have led to alignment on the resubmission process, indicating the FDA's commitment to the drug's approval.
- European Market Progress: The review of the Marketing Authorisation Application (MAA) for Apitegromab in Europe is progressing well, with a decision expected in mid-2026, further supporting the company's global business expansion.
See More
Scholar Rock Resubmits Biologics License Application for SMA Treatment
- Price Target Increase: Raymond James raised Scholar Rock's price target from $53 to $60 while maintaining a ‘Strong Buy’ rating, indicating analysts' confidence in the company's future performance, with expectations of strong market uptake for Apitegromab if approved.
- Regulatory Risk Mitigation: H.C. Wainwright views the resubmission as a ‘material de-risking event’, significantly improving approval chances due to FDA support for manufacturing and increased redundancy, which is expected to accelerate the commercialization process.
- FDA Decision Timeline: The FDA is expected to accept the application within 30 days, followed by a review period of up to six months, with a potential decision by September 2026, providing the company with a clear timeline to prepare for market launch.
- Positive Retail Investor Sentiment: Retail sentiment on Stocktwits shifted from ‘neutral’ to ‘bullish’, indicating strong market interest in Scholar Rock, with the stock gaining approximately 10% year-to-date, reflecting investor confidence in its future potential.
See More
US Stocks Surge as Market Sentiment Improves
- Market Sentiment Improves: The S&P 500 index rose by 1.02%, the Dow Jones Industrial Average increased by 0.67%, and the Nasdaq 100 surged by 1.10% as President Trump signaled a willingness to end military actions against Iran, reflecting investor optimism over easing geopolitical risks.
- Falling Bond Yields: The 10-year Treasury note yield dropped to a one-week low of 4.30%, indicating market expectations that an end to the Iran conflict could lower energy prices and alleviate inflation concerns, further supporting stock market gains.
- Consumer Confidence Rises: The US March consumer confidence index unexpectedly increased by 0.8 to 91.8, surpassing expectations of a decline to 87.9, suggesting enhanced consumer confidence in economic prospects, which could drive spending and economic growth.
- Strong Chinese Economy: China's March manufacturing PMI rose to 50.4, exceeding expectations of 50.1, indicating signs of economic recovery that support global growth prospects and positively influence market performance.
See More
US Stocks Surge as Market Sentiment Improves
- Market Rebound: The S&P 500 Index rose by 1.33%, the Dow Jones Industrial Average increased by 1.10%, and the Nasdaq 100 Index climbed by 1.45%, reflecting investor optimism following President Trump's willingness to end military actions against Iran, potentially easing geopolitical tensions.
- Supportive Economic Data: China's March manufacturing PMI rose by 1.4 to 50.4, surpassing expectations of 50.1, indicating signs of economic recovery that could enhance global growth prospects and drive stock markets higher.
- Falling Bond Yields: The 10-year T-note yield dropped to 4.30%, a one-week low, as WTI crude oil prices fell, alleviating inflation concerns and lowering borrowing costs, thereby supporting further gains in the stock market.
- Tech Stocks Lead Gains: The
See More
Scholar Rock Resubmits Drug Application for Apitegromab, Shares Rise
- Application Resubmission: Scholar Rock announced the resubmission of its U.S. marketing application for apitegromab, aimed at spinal muscular atrophy, resulting in a ~12% premarket share increase, reflecting market optimism regarding potential approval.
- Positive FDA Feedback: Following multiple interactions with the FDA, Scholar Rock confirmed it received guidance on the BLA submission, with no additional corrective actions requested, allowing the company to proceed with the application ahead of Catalent Indiana's reinspection.
- Review Timeline Expectations: The company anticipates that the FDA will accept the BLA within 30 days of resubmission and grant a review period of up to six months, with a potential action date in late September, laying a foundation for future commercialization.
- Ongoing EU Review: The review of Scholar Rock's Marketing Authorization Application for apitegromab in the EU is also underway, with a decision expected in mid-2026, which will further influence the company's international market strategy and development.
See More
Scholar Rock Q4 2025 Earnings Call Insights
- Financial Performance: Scholar Rock reported operating expenses of $91.9 million for Q4 2025, including $19.4 million in noncash stock-based compensation, indicating the company's efforts in cost control while laying the groundwork for future product launches.
- Financial Flexibility: The company ended 2025 with $368 million in cash and cash equivalents and secured a new debt facility of up to $550 million with Blue Owl Capital, enhancing financial flexibility to support the upcoming BLA resubmission and market launch.
- Regulatory Progress: Management reiterated guidance for BLA resubmission of apitegromab in 2026, anticipating FDA approval following a successful reinspection, indicating proactive readiness in regulatory compliance that could expedite product launch timelines.
- Supply Chain Redundancy: Progress has been made on engineering runs at a second fill-finish facility, with plans to file a supplemental BLA later this year, demonstrating a forward-looking approach in supply chain management to mitigate potential production risks and ensure market supply.
See More
